CN Patent

CN109462980B — 用于治疗血液恶性肿瘤的lsd1抑制剂的组合

Assigned to Oryzon Genomics SA · Expires 2022-02-08 · 4y expired

What this patent protects

本发明涉及式(I)的化合物或其药学上可接受的盐与另外的活性药物成分(I)的组合，包含它们的药物组合物及其作为药物、特别是在治疗血液恶性肿瘤中的用途。

USPTO Abstract

本发明涉及式(I)的化合物或其药学上可接受的盐与另外的活性药物成分(I)的组合，包含它们的药物组合物及其作为药物、特别是在治疗血液恶性肿瘤中的用途。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN109462980B
Jurisdiction: CN
Classification: —
Expires: 2022-02-08
Drug substance claim: No
Drug product claim: No
Assignee: Oryzon Genomics SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.